Skip to content
TriangleGet started
← Full study record

NCT02034110 · OUTCOME

Overall Survival (OS) in the Adenocarcinoma of the Small Intestine (ASI) Cohort

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers · Source last updated 2023-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Weeks
Interval / dispersion
95% Confidence Interval
Time frame
From study treatment start date until date of death from any cause, assessed up to 92 months (cut-off date for end of study = 10-Dec-21)

What was measured

Overall Survival (OS) was defined as the time from first dose until death due to any cause. Censoring was performed using the date of last known contact for those who were alive at the time of analysis.

Analysis population: ITT/Evaluable population - Primary analysis cohort

Groups in this outcome

Adenocarcinoma of the Small Intestine (ASI)

All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Adenocarcinoma of the Small Intestine (ASI)3

Reported measurements

Source class 1
Values in Weeks · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Adenocarcinoma of the Small Intestine (ASI)94.6Not reported14.9NANot estimable due to insufficient events observed
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Not estimable due to insufficient events observed
        group Id
        OG000
        lower Limit
        14.9
        upper Limit
        NA
        value
        94.6
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    units
    Participants
description
Overall Survival (OS) was defined as the time from first dose until death due to any cause. Censoring was performed using the date of last known contact for those who were alive at the time of analysis.
dispersion Type
95% Confidence Interval
groups
  1. description
    All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.
    id
    OG000
    title
    Adenocarcinoma of the Small Intestine (ASI)
param Type
MEDIAN
population Description
ITT/Evaluable population - Primary analysis cohort
reporting Status
POSTED
time Frame
From study treatment start date until date of death from any cause, assessed up to 92 months (cut-off date for end of study = 10-Dec-21)
title
Overall Survival (OS) in the Adenocarcinoma of the Small Intestine (ASI) Cohort
type
SECONDARY
unit Of Measure
Weeks

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice